Oxford BioDynamics (GB:OBD) has released an update.
Oxford BioDynamics, a precision clinical diagnostics company, reports growth in test sales and cost reductions after restructuring to focus on its EpiSwitch platform’s PSE and CiRT tests. With a 25% increase in CiRT orders and an 86% increase in PSE test orders in the second half of the financial year, the company has also initiated a strategic review to explore funding options and potentially restructure its US business. This proactive approach comes as the company prepares for additional cash needs by early Q1 of 2025.
For further insights into GB:OBD stock, check out TipRanks’ Stock Analysis page.
